Clinical Trial

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Study acronym: NTS071
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-02; most recent amendment 2026-06-21.
Status change: Not Yet Recruiting → Recruiting 2026-06-15
Trial Details
NCT Number NCT07060989
Lead Sponsor Nutshell Therapeutics (Shanghai) Co., LTD.
Conditions Advanced Solid Tumors
Enrollment 220 participants
Start Date 2025-08-04
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-24